Glenmede Trust Co. NA Grows Position in Certara, Inc. (NASDAQ:CERT)

Glenmede Trust Co. NA grew its position in Certara, Inc. (NASDAQ:CERT) by 78.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,206,069 shares of the company’s stock after purchasing an additional 530,598 shares during the period. Glenmede Trust Co. NA’s holdings in Certara were worth $14,123,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Blue Trust Inc. acquired a new position in Certara during the second quarter valued at approximately $26,000. Innealta Capital LLC purchased a new position in shares of Certara in the 2nd quarter valued at $36,000. KBC Group NV lifted its holdings in shares of Certara by 48.2% during the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after acquiring an additional 1,584 shares in the last quarter. Intech Investment Management LLC purchased a new stake in Certara during the 2nd quarter worth $152,000. Finally, Algert Global LLC acquired a new stake in Certara in the 2nd quarter valued at $156,000. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on CERT. UBS Group upgraded Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Friday, September 27th. Barclays reduced their price target on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, November 7th. Finally, Robert W. Baird lowered their price objective on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research report on Tuesday, November 5th. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $15.92.

Insider Transactions at Certara

In related news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the sale, the insider now directly owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. This represents a 33.94 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction on Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the transaction, the insider now directly owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. This represents a 9.75 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.39% of the company’s stock.

Certara Stock Performance

Shares of CERT opened at $11.27 on Friday. The firm has a market cap of $1.81 billion, a price-to-earnings ratio of -56.35, a PEG ratio of 5.59 and a beta of 1.51. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The business’s 50 day moving average is $10.81 and its two-hundred day moving average is $13.07. Certara, Inc. has a 52-week low of $9.41 and a 52-week high of $19.87.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. The firm had revenue of $94.80 million for the quarter, compared to the consensus estimate of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm’s revenue was up 10.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.06 EPS. Analysts forecast that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.